278 related articles for article (PubMed ID: 36233356)
21. Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan.
Yu WR; Kuo HC
Low Urin Tract Symptoms; 2024 Jan; 16(1):e12508. PubMed ID: 37987028
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil-to-lymphocyte ratio as a promising non-invasive biomarker for symptom assessment and diagnosis of interstitial cystitis/bladder pain syndrome.
Ke H; Zhu L; Wang Q; Xu K
BMC Urol; 2023 Nov; 23(1):180. PubMed ID: 37940904
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis.
Niimi A; Igawa Y; Aizawa N; Honma T; Nomiya A; Akiyama Y; Kamei J; Fujimura T; Fukuhara H; Homma Y
Neurourol Urodyn; 2018 Mar; 37(3):1113-1119. PubMed ID: 29048741
[TBL] [Abstract][Full Text] [Related]
24. Urinary Oxidative Stress Biomarker Levels Might Be Useful in Identifying Functional Bladder Disorders in Women with Frequency and Urgency Syndrome.
Jiang YH; Jhang JF; Kuo HC
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983336
[TBL] [Abstract][Full Text] [Related]
25. Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome.
Yu WR; Jhang JF; Kuo HC
Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393152
[TBL] [Abstract][Full Text] [Related]
26. Anesthetic Bladder Capacity is a Clinical Biomarker for Interstitial Cystitis/Bladder Pain Syndrome Subtypes.
Plair A; Evans RJ; Langefeld CD; Matthews CA; Badlani G; Walker SJ
Urology; 2021 Dec; 158():74-80. PubMed ID: 34303757
[TBL] [Abstract][Full Text] [Related]
27. Voiding dysfunctions in patients with non-Hunner's ulcer interstitial cystitis/bladder pain syndrome do not affect long-term treatment outcome.
Yu WR; Chang WC; Kuo HC
Int J Clin Pract; 2021 Sep; 75(9):e14372. PubMed ID: 33998747
[TBL] [Abstract][Full Text] [Related]
28. Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome.
Schachar JS; Evans RJ; Parks GE; Zambon J; Badlani G; Walker SJ
Int Urogynecol J; 2019 Nov; 30(11):1863-1870. PubMed ID: 31254048
[TBL] [Abstract][Full Text] [Related]
29. Urothelial Functional Protein and Sensory Receptors in Patients With Interstitial Cystitis/Bladder Pain Syndrome With and Without Hunner's Lesion.
Jhang JF; Hsu YH; Kuo HC
Urology; 2016 Dec; 98():44-49. PubMed ID: 27575016
[TBL] [Abstract][Full Text] [Related]
30. Hunner-Type (Classic) Interstitial Cystitis: A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation.
Maeda D; Akiyama Y; Morikawa T; Kunita A; Ota Y; Katoh H; Niimi A; Nomiya A; Ishikawa S; Goto A; Igawa Y; Fukayama M; Homma Y
PLoS One; 2015; 10(11):e0143316. PubMed ID: 26587589
[TBL] [Abstract][Full Text] [Related]
31. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment.
Liu HT; Tyagi P; Chancellor MB; Kuo HC
BJU Int; 2009 Nov; 104(10):1476-81. PubMed ID: 19522864
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion.
Choi D; Han JY; Shin JH; Ryu CM; Yu HY; Kim A; Lee S; Lim J; Shin DM; Choo MS
Sci Rep; 2018 Jun; 8(1):9782. PubMed ID: 29955137
[TBL] [Abstract][Full Text] [Related]
33. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid.
Jiang YH; Liu HT; Kuo HC
PLoS One; 2014; 9(3):e91609. PubMed ID: 24614892
[TBL] [Abstract][Full Text] [Related]
34. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C.
Gamper M; Viereck V; Eberhard J; Binder J; Moll C; Welter J; Moser R
Int Urogynecol J; 2013 Dec; 24(12):2049-57. PubMed ID: 23670165
[TBL] [Abstract][Full Text] [Related]
35. Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.
Lin HY; Lu JH; Chuang SM; Chueh KS; Juan TJ; Liu YC; Juan YS
Diagnostics (Basel); 2021 Dec; 12(1):. PubMed ID: 35054241
[TBL] [Abstract][Full Text] [Related]
36. Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome.
Jhang JF; Jiang YH; Kuo HC
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289642
[TBL] [Abstract][Full Text] [Related]
37. Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients.
Vera PL; Preston DM; Moldwin RM; Erickson DR; Mowlazadeh B; Ma F; Kouzoukas DE; Meyer-Siegler KL; Fall M
Urology; 2018 Jun; 116():55-62. PubMed ID: 29580781
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers of ocular allergy and dry eye disease.
Zemba M; Ionescu MA; Pîrvulescu RA; Dumitrescu OM; Daniel-Constantin B; Radu M; Stamate AC; Istrate S
Rom J Ophthalmol; 2023; 67(3):250-259. PubMed ID: 37876509
[TBL] [Abstract][Full Text] [Related]
39. Multimodal Single-Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome.
Su F; Zhang W; Meng L; Zhang W; Liu X; Liu X; Chen M; Zhang Y; Xiao F
Adv Sci (Weinh); 2022 Jun; 9(18):e2106063. PubMed ID: 35470584
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis of bladder biopsies from interstitial cystitis/bladder pain syndrome patients with and without Hunner's lesions reveals differences in expression of inflammatory and structural proteins.
Ward EP; Bartolone SN; Chancellor MB; Peters KM; Lamb LE
BMC Urol; 2020 Nov; 20(1):180. PubMed ID: 33160333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
